Osteoprotegerin induces apoptosis of osteoclasts and osteoclast precursor cells via the fas/fas ligand pathway

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Liu, Wei ^a   Xu, Chao ^a   Zhao, Hongyan ^a   Xia, Pengpeng ^a   Song, Ruilong ^a   Gu, Jianhong ^a   Liu, Xuezhong ^a   Bian, Jianchun ^a   Yuan, Yan ^a   Liu, Zongping ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; FAS LIGAND; OSTEOPROTEGERIN; PROTEIN BAX; PROTEIN BCL 2; FAS ANTIGEN; FAS PROTEIN, MOUSE; TNFRSF11B PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; IMMUNOPRECIPITATION; MALE; MITOCHONDRION; MOUSE; NONHUMAN; OSTEOCLAST; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; METABOLISM; OSTEOBLAST; PHYSIOLOGY; SOLUBILITY;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELLS, CULTURED; FAS LIGAND PROTEIN; MALE; MICE; MICE, INBRED BALB C; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; SIGNAL TRANSDUCTION; SOLUBILITY;

EID: 84956688452     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142519     Document Type: Article

References (44)

1. Ware CF. The TNF Superfamily-2008. Cytokine Growth F R 2008; 19(3-4):183-6.
2. Grewal IS. Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv Exp Med Biol. 2009; 647:1-7. doi: 10.1007/978-0-387-89520-8-1 PMID: 19760063
3. Baud'huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, et al. Osteoprotegerin: Multiple partners for multiple functions. Cytokine Growth F R 2013.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. PMID: 9108485
5. Tsuda E, Goto M, Mochizuki S-i, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis. Biochem Biophys Res Commun 1997; 234(1):137-42. PMID: 9168977
6. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2000; 11(11):905-13. PMID: 11193242
7. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005; 5(6):618-25. PMID: 16188502
8. Zhao H, Liu X, Zou H, Dai N, Yao L, Gao Q, et al. Osteoprotegerin induces podosome disassembly in osteoclasts through calcium, ERK, and p38 MAPK signaling pathways. Cytokine. 2015; 71(2):199-206. doi: 10.1016/j.cyto.2014.10.007 PMID: 25461399
9. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000; 157(2):435-48. PMID: 10934148
10. Shinohara M, Takayanagi H. Novel osteoclast signaling mechanisms. Curr Osteoporos Rep. 2007; 5 (2):67-72. PMID: 17521508
11. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995; 267 (5203):1456-62. PMID: 7878464
12. Robertson JD, Orrenius S, Zhivotovsky B. Review: nuclear events in apoptosis. J Struct Biol. 2000; 129 (2-3):346-58. PMID: 10806085
13. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, et al. Cell death: apoptosis versus necrosis (review). Int J Oncol. 2002; 21(1):165-70. PMID: 12063564
14. Gupta S. Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). Int J Oncol. 2003; 22(1):15-20. PMID: 12469180
15. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4):495-516. PMID: 17562483
16. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999; 33:29-55. PMID: 10690403
17. Seeman E. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int. 2003; 14 Suppl 3:S2-8. PMID: 12730770
18. Grcevic D, Katavic V, Lukic IK, Kovacic N, Lorenzo JA, Marusic A. Cellular and molecular interactions between immune system and bone. Croat Med J. 2001; 42(4):384-92. PMID: 11471190
19. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, et al. Estrogen prevents bone loss via estrogen receptor a and induction of Fas ligand in osteoclasts. Cell. 2007; 130(5):811-23. PMID: 17803905
20. Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, et al. Regulation of adult bone turnover by sex steroids. J Cell Physiol. 2010; 224(2):305-10. doi: 10.1002/jcp.22159 PMID: 20432458
21. Kovacic N, Lukic IK, Grcevic D, Katavic V, Croucher P, Marusic A. The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol. 2007; 178(6):3379-89. PMID: 17339432
22. Yuan Y, Jiang CY, Xu H, Sun Y, Hu FF, Bian JC, et al. Cadmium-Induced Apoptosis in Primary Rat Cerebral Cortical Neurons Culture Is Mediated by a Calcium Signaling Pathway. Plos One. 2013; 8(5).
23. Greenfield EM, Bi Y, Miyauchi A. Regulation of osteoclast activity. Life Sci. 1999; 65(11):1087-102. PMID: 10503925
24. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21(2):115-37. PMID: 10782361
25. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995; 10(10):1478-87. PMID: 8686503
26. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996; 2(10):1132-6. PMID: 8837613
27. Kameda T, Miyazawa K, Mori Y, Yuasa T, Shiokawa M, Nakamaru Y, et al. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun. 1996; 220 (3):515-9. PMID: 8607797
28. Marie P, Halbout P. [OPG/RANKL: role and therapeutic target in osteoporosis]. Med Sci (Paris). 2008; 24(1):105-10.
29. Ando K, Mori K, Redini F, Heymann D. RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol. 2008; 5(3):263-8. PMID: 18690894
30. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med. 2009; 58(1):29-40. PMID: 19398882
31. Chamoux E, Houde N, L'Eriger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 2008; 216(2):536-42. doi: 10.1002/jcp.21430 PMID: 18338379
32. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273(23):14363-7. PMID: 9603945
33. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2):157-63. PMID: 9930862
34. Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 2007; 67(1):202-8. PMID: 17210700
35. Sharma K, Wang R, Zhang L, Yin D, Luo X, Solomon J, et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Therapeut. 2000; 88(3):333-47.
36. Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun. 2005; 333(1):42-50. PMID: 15936719
37. Marusic A, Kovacic N, Lukic IK, Katavic V, Grcevic D. Understanding the role of Fas-Fas ligand system in bone. Arthritis Res Ther. 2012; 14.
38. Katavic V, Lukic IK, Kovacic N, Grcevic D, Lorenzo JA, Marusic A. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol. 2003; 170(3):1540-7. PMID: 12538719
39. Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology. 2003; 144(12):5545-55. PMID: 12960091
40. Wang L, Liu S, Zhao Y, Liu D, Liu Y, Chen C, et al. Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass. Cell Death & Differentiation. 2015.
41. Park H, Jung YK, Park OJ, Lee YJ, Choi JY, Choi Y. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol. 2005; 175(11):7193-201. PMID: 16301623
42. Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, Terskikh A, et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem. 1997; 272(30):18827-33. PMID: 9228058
43. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997; 186(12):2045-50. PMID: 9396774
44. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998; 4 (1):31-6. PMID: 9427603